Is Mazdutide Better Than Retatrutide? A Complete Comparison

No head-to-head clinical trial has ever compared mazdutide and retatrutide, so there is no evidence-based answer to whether mazdutide is better than retatrutide. Based on separate trials, retatrutide has produced larger average weight loss at its highest dose, while mazdutide is further along in the regulatory process in China. Neither drug is approved by the FDA for human use in the United States.

What Each Drug Actually Targets

Mazdutide (IBI362) is a dual agonist that activates the GLP-1 and glucagon receptors. It is being developed by Innovent Biologics in partnership with Eli Lilly and has been submitted for approval in China for chronic weight management.

Retatrutide (LY3437943) is a triple agonist that activates the GLP-1, GIP, and glucagon receptors. Eli Lilly is running it through a large Phase 3 program called TRIUMPH.

The extra GIP arm is the biggest mechanistic difference between the two. Adding glucagon agonism is thought to increase energy expenditure and may improve liver fat, but glucagon is also the receptor most likely to drive resting heart-rate increases.

A related search, mazdutide vs survodutide vs retatrutide, comes up often because survodutide is another GLP-1/glucagon dual agonist. Mazdutide is not the only dual-agonist candidate in development.

Is retatrutide a GLP-3?

No. GLP-3 is not an official receptor or drug class. People who search is retatrutide a glp-3 are usually trying to describe its three-receptor mechanism, but researchers call it a triple agonist. The GLP-3 label is internet shorthand, not pharmacology.

Mazdutide vs Retatrutide: Weight Loss Results Compared

Both drugs are given as once-weekly subcutaneous injections. Their headline weight-loss numbers come from different trials, in different populations, at different doses.

Feature	Mazdutide	Retatrutide
Developer	Innovent Biologics / Eli Lilly	Eli Lilly
Receptor targets	GLP-1 + glucagon	GLP-1 + GIP + glucagon
Highest phase	Phase 3, filed in China	Phase 3 (TRIUMPH)
Dosing	Weekly injection	Weekly injection
Mean weight loss reported	Roughly 12-15% at 48 weeks (6 mg)	Roughly 24% at 48 weeks (12 mg)
FDA status	Not approved	Not approved

Retatrutide's 12 mg dose produced about 24% mean weight reduction at 48 weeks in a Phase 2 trial of adults with obesity. Mazdutide's Phase 3 GLORY-1 trial reported weight reductions in the low-to-mid teens at 48 weeks for the 6 mg dose, with higher doses still under study.

Those figures should not be treated as a scoreboard. Retatrutide's early trials enrolled mostly US adults, while mazdutide's Phase 3 data come largely from Chinese adults with different baseline body weights and diets. Cross-trial comparisons in obesity medicine are unreliable, and no trial has randomized patients to both drugs.

Side Effects and Safety Signals

Both compounds share the GI side effects typical of incretin drugs. The glucagon component adds a few signals worth watching.

• Nausea, vomiting, diarrhea, and constipation are the most common complaints for both drugs.
• Resting heart rate tends to rise with glucagon agonism; retatrutide's Phase 2 data showed increases of several beats per minute.
• Injection-site reactions, gallbladder events, and pancreatitis are class-level concerns for GLP-1-based drugs.
• Long-term safety is unknown for both, because neither has been through post-marketing surveillance.

People asking is reta safer than ozempic should remember that semaglutide has years of real-world safety data behind it, while retatrutide has none outside of trials. That evidence gap matters more right now than receptor count.

If you are weighing approved options instead, tirzepatide vs semaglutide which is better for weight loss is a question that at least has head-to-head trial data behind it.

Availability and Legal Status in the US

Mazdutide and retatrutide are both investigational in the United States. The only legitimate way to obtain either one is enrollment in a clinical trial.

Both compounds also circulate on the gray market as lyophilized research chemicals. Vials sold that way are not reviewed by the FDA for identity, sterility, or dose accuracy, and potency can vary widely between batches.

People searching bac water what is it are usually trying to reconstitute those freeze-dried vials at home. That practice adds contamination risk on top of an unverified drug, and it is not a substitute for medical care.

Anyone considering a weight-loss medication should talk with a healthcare professional before starting, stopping, or stacking any product.

Why Mazdutide vs Retatrutide Reddit Threads Aren't Evidence

Searching mazdutide vs retatrutide reddit turns up plenty of personal reports, but those posts cannot answer which drug is better.

• Users are self-selected, and people who lose weight are more likely to post than people who quit.
• The vial in a forum photo is rarely verified, so the compound and dose are unknown.
• Many posters stack multiple peptides, which makes any single drug's effect impossible to isolate.
• Without baseline labs, follow-up labs, or a control group, anecdotes cannot separate drug effect from diet, exercise, or placebo.

The Bottom Line

• There is no head-to-head trial comparing mazdutide and retatrutide, so the question of which is better cannot be answered with data.
• Retatrutide has shown larger average weight loss in its own trials, but those results come from different populations and study designs than mazdutide's.
• Mazdutide is closer to market in China, while retatrutide is still working through Phase 3.
• Neither drug is FDA-approved, and both carry unknown long-term risks.
• Approved options such as semaglutide and tirzepatide remain the standard of care for weight management in the US.

COMMON QUESTIONS

Frequently Asked Questions

Is mazdutide better than retatrutide for weight loss?

No head-to-head trial has compared the two drugs, so no one can say for certain. In separate studies, retatrutide 12 mg produced roughly 24% mean weight loss at 48 weeks, while mazdutide 6 mg produced roughly 12-15% at 48 weeks. Those results come from different populations and study designs, so they cannot be compared directly.

Is retatrutide a GLP-3?

No. GLP-3 is not an official receptor or drug class. Retatrutide is a triple agonist that targets the GLP-1, GIP, and glucagon receptors, which is why people sometimes describe it informally as a GLP-3.

Can I buy mazdutide or retatrutide in the US?

Neither drug is FDA-approved, so you cannot get a legitimate prescription in the United States. Both are available only through clinical trials. Products sold online as research chemicals are unregulated and may be mislabeled, underdosed, or contaminated.